Allogene Therapeutics Inc (NAS:ALLO)
$ 2.14 -0.05 (-2.28%) Market Cap: 459.18 Mil Enterprise Value: 269.53 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 37/100

Allogene Therapeutics Inc at B Riley Securities Oncology Conference (Virtual) Transcript

Jan 18, 2023 / 03:00PM GMT
Release Date Price: $6.46 (-7.05%)
Kalpit R. Patel
B. Riley Securities, Inc., Research Division - Healthcare Research Analyst

Okay. Good morning, everyone, and welcome to B. Riley's Oncology Conference. I'm Kalpit Patel, a research analyst here at B. Riley. And it's my pleasure to introduce our first fireside chat of the day, with Allogene's CFO, Eric Schmidt.

If anyone in the audience has any questions for Eric, please feel free to e-mail me at [email protected].

Eric, it's great to have you join us today. Welcome.

Questions & Answers

Kalpit R. Patel
B. Riley Securities, Inc., Research Division - Healthcare Research Analyst

Maybe to start, let's dive right into the data that you've showed at your November R&D showcase. I want to specifically dig into the durability data that you've shown for ALLO-501, 501A. There was a nice slide in there with the swimmers plot that was outlined, which essentially showed how patients performed over a long period of time, the patients who achieved a CR.

Can you give us a sense of how closely this durability

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot